← All trials
NCT01501695
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- Nov 1, 2010
- Completion date
- Oct 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 603
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Tasly Pharmaceuticals, Inc.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Nanjing UniversityOverall official - principal investigator
- Tianjin University of Traditional Chinese MedicineOverall official - principal investigator
- Liaoning Hospital of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.